1. Basse, M.J., et al., 2P2Idb v2: update of a structural database dedicated to orthosteric modulation of protein-protein interactions. Database (Oxford), 2016. 2016.
2. Higueruelo, A.P., H. Jubb, and T.L. Blundell, TIMBAL v2: update of a database holding small molecules modulating protein-protein interactions. Database (Oxford), 2013. 2013: p. bat039.
3. Labbe, C.M., et al., iPPI-DB: an online database of modulators of protein-protein interactions. Nucleic Acids Res, 2016. 44(D1): p. D542-7.
4. Shin, W.H., C.W. Christoffer, and D. Kihara, In silico structure-based approaches to discover protein-protein interaction-targeting drugs. Methods, 2017. 131: p. 22-32.
5. Wang, Z., et al., Benchmark Study Based on 2P2IDB to Gain Insights into the Discovery of Small-Molecule PPI Inhibitors. J Phys Chem B, 2018. 122(9): p. 2544-2555.
6. Quemener, A., et al., Discovery of a Small-Molecule Inhibitor of Interleukin 15: Pharmacophore-Based Virtual Screening and Hit Optimization. J Med Chem, 2017. 60(14): p. 6249-6272.
7. Tsuburaya, N., et al., A small-molecule inhibitor of SOD1-Derlin-1 interaction ameliorates pathology in an ALS mouse model. Nat Commun, 2018. 9(1): p. 2668.
8. Bille, A., et al., Local unfolding and aggregation mechanisms of SOD1: a Monte Carlo exploration. J Phys Chem B, 2013. 117(31): p. 9194-202.
9. Healy, E.F., A mechanism for propagated SOD1 misfolding from frustration analysis of a G85R mutant protein assembly. Biochem Biophys Res Commun, 2016. 478(4): p. 1634-9.
10. Logroscino, G., et al., Incidence of amyotrophic lateral sclerosis in Europe. J Neurol Neurosurg Psychiatry, 2010. 81(4): p. 385-90.
11. Byrne, S., et al., Absence of consensus in diagnostic criteria for familial neurodegenerative diseases. J Neurol Neurosurg Psychiatry, 2012. 83(4): p. 365-7.
12. Al-Chalabi, A. and C.M. Lewis, Modelling the effects of penetrance and family size on rates of sporadic and familial disease. Hum Hered, 2011. 71(4): p. 281-8.
13. Abel, O., et al., ALSoD: A user-friendly online bioinformatics tool for amyotrophic lateral sclerosis genetics. Hum Mutat, 2012. 33(9): p. 1345-51.
14. Alsultan, A.A., et al., The genetics of amyotrophic lateral sclerosis: current insights. Degener Neurol Neuromuscul Dis, 2016. 6: p. 49-64.
15. Morgan, S., et al., A comprehensive analysis of rare genetic variation in amyotrophic lateral sclerosis in the UK. Brain, 2017. 140(6): p. 1611-1618.
16. Gurney, M.E., et al., Motor-Neuron Degeneration in Mice That Express a Human Cu,Zn Superoxide-Dismutase Mutation. Science, 1994. 264(5166): p. 1772-1775.
17. Reaume, A.G., et al., Motor neurons in Cu/Zn superoxide dismutase-deficient mice develop normally but exhibit enhanced cell death after axonal injury. Nat Genet, 1996. 13(1): p. 43-7.
18. Kabuta, T., et al., Familial amyotrophic lateral sclerosis-linked mutant SOD1 aberrantly interacts with tubulin. Biochem Biophys Res Commun, 2009. 387(1): p. 121-6.
19. Ilieva, H., M. Polymenidou, and D.W. Cleveland, Non-cell autonomous toxicity in neurodegenerative disorders: ALS and beyond. J Cell Biol, 2009. 187(6): p. 761-72.
20. Dervishi, I. and P.H. Ozdinler, Incorporating upper motor neuron health in ALS drug discovery. Drug Discov Today, 2018. 23(3): p. 696-703.
21. Perry, J.J., et al., The structural biochemistry of the superoxide dismutases. Biochim Biophys Acta, 2010. 1804(2): p. 245-62.
22. Yonashiro, R., et al., Mitochondrial ubiquitin ligase MITOL ubiquitinates mutant SOD1 and attenuates mutant SOD1-induced reactive oxygen species generation. Mol Biol Cell, 2009. 20(21): p. 4524-30.
23. Pratt, A.J., et al., Aggregation propensities of superoxide dismutase G93 hotspot mutants mirror ALS clinical phenotypes. Proc Natl Acad Sci U S A, 2014. 111(43): p. E4568-76.
24. McRee, D.E., et al., Changes in crystallographic structure and thermostability of a Cu,Zn superoxide dismutase mutant resulting from the removal of a buried cysteine. J Biol Chem, 1990. 265(24): p. 14234-41.
25. Lepock, J.R., H.E. Frey, and R.A. Hallewell, Contribution of conformational stability and reversibility of unfolding to the increased thermostability of human and bovine superoxide dismutase mutated at free cysteines. J Biol Chem, 1990. 265(35): p. 21612-8.
26. Nakamura, A., et al., Marked intrafamilial phenotypic variation in a family with SOD1 C111Y mutation. Amyotroph Lateral Scler, 2012. 13(5): p. 479-86.
27. Wang, Z., et al., Identification of a novel missense (C7W) mutation of SOD1 in a large familial amyotrophic lateral sclerosis pedigree. Neurobiol Aging, 2014. 35(3): p. 725 e11-5.
28. DiDonato, M., et al., ALS mutants of human superoxide dismutase form fibrous aggregates via framework destabilization. J Mol Biol, 2003. 332(3): p. 601-15.
29. Culotta, V.C., M. Yang, and T.V. O'Halloran, Activation of superoxide dismutases: putting the metal to the pedal. Biochim Biophys Acta, 2006. 1763(7): p. 747-58.
30. Banci, L., et al., Structure and dynamics of copper-free SOD: The protein before binding copper. Protein Sci, 2002. 11(10): p. 2479-92.
31. Strange, R.W., et al., The structure of holo and metal-deficient wild-type human Cu, Zn superoxide dismutase and its relevance to familial amyotrophic lateral sclerosis. J Mol Biol, 2003. 328(4): p. 877-91.
32. Strange, R.W., et al., Molecular dynamics using atomic-resolution structure reveal structural fluctuations that may lead to polymerization of human Cu-Zn superoxide dismutase. Proc Natl Acad Sci U S A, 2007. 104(24): p. 10040-4.
33. Cao, X., et al., Structures of the G85R variant of SOD1 in familial amyotrophic lateral sclerosis. J Biol Chem, 2008. 283(23): p. 16169-77.
34. Arnesano, F., et al., The unusually stable quaternary structure of human Cu,Zn-superoxide dismutase 1 is controlled by both metal occupancy and disulfide status. J Biol Chem, 2004. 279(46): p. 47998-8003.
35. Higashi, S., et al., TDP-43 physically interacts with amyotrophic lateral sclerosis-linked mutant CuZn superoxide dismutase. Neurochem Int, 2010. 57(8): p. 906-13.
36. Nishitoh, H., et al., ALS-linked mutant SOD1 induces ER stress- and ASK1-dependent motor neuron death by targeting Derlin-1. Genes Dev, 2008. 22(11): p. 1451-64.
37. Tateno, M., et al., Mutant SOD1 impairs axonal transport of choline acetyltransferase and acetylcholine release by sequestering KAP3. Hum Mol Genet, 2009. 18(5): p. 942-55.
38. Araki, T., et al., Misfolded SOD1 forms high-density molecular complexes with synaptic molecules in mutant SOD1-linked familial amyotrophic lateral sclerosis cases. J Neurol Sci, 2012. 314(1-2): p. 92-6.
39. Shvil, N., et al., MIF inhibits the formation and toxicity of misfolded SOD1 amyloid aggregates: implications for familial ALS. Cell Death Dis, 2018. 9(2): p. 107.
40. Niwa, J., et al., Dorfin ubiquitylates mutant SOD1 and prevents mutant SOD1-mediated neurotoxicity. J Biol Chem, 2002. 277(39): p. 36793-8.
41. Antonyuk, S., et al., Structural consequences of the familial amyotrophic lateral sclerosis SOD1 mutant His46Arg. Protein Sci, 2005. 14(5): p. 1201-13.
42. Elam, J.S., et al., An alternative mechanism of bicarbonate-mediated peroxidation by copper-zinc superoxide dismutase: rates enhanced via proposed enzyme-associated peroxycarbonate intermediate. J Biol Chem, 2003. 278(23): p. 21032-9.
43. Coelho, F.R., et al., Oxidation of the tryptophan 32 residue of human superoxide dismutase 1 caused by its bicarbonate-dependent peroxidase activity triggers the non-amyloid aggregation of the enzyme. J Biol Chem, 2014. 289(44): p. 30690-701.
44. Medinas, D.B., et al., A ditryptophan cross-link is responsible for the covalent dimerization of human superoxide dismutase 1 during its bicarbonate-dependent peroxidase activity. Free Radic Biol Med, 2010. 49(6): p. 1046-53.
45. Pokrishevsky, E., et al., Tryptophan 32-mediated SOD1 aggregation is attenuated by pyrimidine-like compounds in living cells. Sci Rep, 2018. 8(1): p. 15590.
46. Bruijn, L.I., et al., ALS-linked SOD1 mutant G85R mediates damage to astrocytes and promotes rapidly progressive disease with SOD1-containing inclusions. Neuron, 1997. 18(2): p. 327-38.
47. Jones, G., et al., Development and validation of a genetic algorithm for flexible docking. J Mol Biol, 1997. 267(3): p. 727-48.
48. Friesner, R.A., et al., Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem, 2004. 47(7): p. 1739-49.
49. McNally, V.A., et al., Identification of a novel class of inhibitor of human and Escherichia coli thymidine phosphorylase by in silico screening. Bioorg Med Chem Lett, 2003. 13(21): p. 3705-9.
50. Peng, H., et al., Identification of novel inhibitors of BCR-ABL tyrosine kinase via virtual screening. Bioorg Med Chem Lett, 2003. 13(21): p. 3693-9.
51. Dong, X., et al., The rational design of specific SOD1 inhibitors via copper coordination and their application in ROS signaling research. Chem Sci, 2016. 7(9): p. 6251-6262.
52. Xu, Y., et al., Discovery of Novel Inhibitors Targeting the Menin-Mixed Lineage Leukemia Interface Using Pharmacophore- and Docking-Based Virtual Screening. J Chem Inf Model, 2016. 56(9): p. 1847-55.
53. Tortorella, P., et al., An Effective Virtual Screening Protocol To Identify Promising p53-MDM2 Inhibitors. J Chem Inf Model, 2016. 56(6): p. 1216-27.
54. Prudencio, M., et al., Variation in aggregation propensities among ALS-associated variants of SOD1: correlation to human disease. Hum Mol Genet, 2009. 18(17): p. 3217-26.
55. Banerjee, V., et al., A computational combinatorial approach identifies a protein inhibitor of superoxide dismutase 1 misfolding, aggregation, and cytotoxicity. J Biol Chem, 2017. 292(38): p. 15777-15788.
56. Ray, S.S., et al., Small-molecule-mediated stabilization of familial amyotrophic lateral sclerosis-linked superoxide dismutase mutants against unfolding and aggregation. Proc Natl Acad Sci U S A, 2005. 102(10): p. 3639-44.
57. Lagarias, P., et al., Discovery of Novel Adenosine Receptor Antagonists through a Combined Structure- and Ligand-Based Approach Followed by Molecular Dynamics Investigation of Ligand Binding Mode. Journal of Chemical Information and Modeling, 2018. 58(4): p. 794-815.
58. Oyallon, B., et al., Structure-based design of novel quinoxaline-2-carboxylic acids and analogues as Pim-1 inhibitors. European Journal of Medicinal Chemistry, 2018. 154: p. 101-109.
59. Ramsbeck, D., et al., Structure-Guided Design, Synthesis, and Characterization of Next-Generation Meprin beta Inhibitors. Journal of Medicinal Chemistry, 2018. 61(10): p. 4578-4592.
60. Karatas, H., et al., Discovery of a Highly Potent, Cell-Permeable Macrocyclic Peptidomimetic (MM-589) Targeting the WD Repeat Domain 5 Protein (WDR5)-Mixed Lineage Leukemia (MLL) Protein-Protein Interaction. J Med Chem, 2017. 60(12): p. 4818-4839.
61. Naret, T., et al., A fluorine scan of a tubulin polymerization inhibitor isocombretastatin A-4: Design, synthesis, molecular modelling, and biological evaluation. Eur J Med Chem, 2018. 143: p. 473-490.
62. Villa, S., et al., Structure-based drug design, synthesis and biological assays of P. falciparum Atg3-Atg8 protein-protein interaction inhibitors. J Comput Aided Mol Des, 2018. 32(3): p. 473-486.
63. Zhou, H., et al., High-Affinity Peptidomimetic Inhibitors of the DCN1-UBC12 Protein-Protein Interaction. J Med Chem, 2018. 61(5): p. 1934-1950.
64. Newkirk, M.L., et al., Analysis of MEMO1 Binding Specificity for ErbB2 Using Fluorescence Polarization and Molecular Dynamics Simulations. Biochemistry, 2018. 57(34): p. 5169-5181.
65. Taechalertpaisarn, J., et al., Small Molecule Inhibitors of the PCSK9.LDLR Interaction. J Am Chem Soc, 2018. 140(9): p. 3242-3249.
66. Pettersen, E.F., et al., UCSF Chimera--a visualization system for exploratory research and analysis. J Comput Chem, 2004. 25(13): p. 1605-12.
67. Hendlich, M., F. Rippmann, and G. Barnickel, LIGSITE: automatic and efficient detection of potential small molecule-binding sites in proteins. J Mol Graph Model, 1997. 15(6): p. 359-63, 389.
68. Hirayama, K., et al., Virtual screening identification of novel chemical inhibitors for aberrant interactions between pathogenic mutant SOD1 and tubulin. Neurochem Int, 2019. 126: p. 19-26.
69. Brylinski, M., Aromatic interactions at the ligand-protein interface: Implications for the development of docking scoring functions. Chem Biol Drug Des, 2018. 91(2): p. 380-390.
70. Fang, Y. and X. Shen, Ubiquitin carboxyl-terminal hydrolases: involvement in cancer progression and clinical implications. Cancer Metastasis Rev, 2017. 36(4): p. 669-682.
71. Ciechanover, A. and A.L. Schwartz, The ubiquitin-proteasome pathway: the complexity and myriad functions of proteins death. Proc Natl Acad Sci U S A, 1998. 95(6): p. 2727-30.
72. Pickart, C.M. and I.A. Rose, Ubiquitin carboxyl-terminal hydrolase acts on ubiquitin carboxyl-terminal amides. J Biol Chem, 1985. 260(13): p. 7903-10.
73. Kaushal, K., et al., Deubiquitinating enzymes in cancer stem cells: functions and targeted inhibition for cancer therapy. Drug Discov Today, 2018. 23(12): p. 1974-1982.
74. Setsuie, R., et al., Ubiquitin dimers control the hydrolase activity of UCH-L3. Neurochem Int, 2009. 54(5-6): p. 314-21.
75. Misaghi, S., et al., Structure of the ubiquitin hydrolase UCH-L3 complexed with a suicide substrate. J Biol Chem, 2005. 280(2): p. 1512-20.
76. Suzuki, M., R. Setsuie, and K. Wada, Ubiquitin carboxyl-terminal hydrolase l3 promotes insulin signaling and adipogenesis. Endocrinology, 2009. 150(12): p. 5230-9.
77. Kwon, J., et al., Two closely related ubiquitin C-terminal hydrolase isozymes function as reciprocal modulators of germ cell apoptosis in cryptorchid testis. Am J Pathol, 2004. 165(4): p. 1367-74.
78. Sano, Y., et al., Photoreceptor cell apoptosis in the retinal degeneration of Uchl3-deficient mice. Am J Pathol, 2006. 169(1): p. 132-41.
79. Lipinski, C.A., Rule of five in 2015 and beyond: Target and ligand structural limitations, ligand chemistry structure and drug discovery project decisions. Adv Drug Deliv Rev, 2016. 101: p. 34-41.
80. Nishikawa, K., et al., Alterations of structure and hydrolase activity of parkinsonism-associated human ubiquitin carboxyl-terminal hydrolase L1 variants. Biochem Biophys Res Commun, 2003. 304(1): p. 176-83.
81. Liu, Y., et al., Discovery of inhibitors that elucidate the role of UCH-L1 activity in the H1299 lung cancer cell line. Chem Biol, 2003. 10(9): p. 837-46.
82. Hirayama, K., et al., Identification of novel chemical inhibitors for ubiquitin C-terminal hydrolase-L3 by virtual screening. Bioorg Med Chem, 2007. 15(21): p. 6810-8.
83. Pan, M., et al., Chemical Protein Synthesis Enabled Mechanistic Studies on the Molecular Recognition of K27-linked Ubiquitin Chains. Angew Chem Int Ed Engl, 2019. 58(9): p. 2627-2631.
84. Miyoshi, Y., et al., High expression of ubiquitin carboxy-terminal hydrolase-L1 and -L3 mRNA predicts early recurrence in patients with invasive breast cancer. Cancer Sci, 2006. 97(6): p. 523-9.
85. Rolen, U., et al., Activity profiling of deubiquitinating enzymes in cervical carcinoma biopsies and cell lines. Mol Carcinog, 2006. 45(4): p. 260-9.
86. Wilkinson, K.D., et al., The neuron-specific protein PGP 9.5 is a ubiquitin carboxyl-terminal hydrolase. Science, 1989. 246(4930): p. 670-3.
87. Momose, Y., et al., Association studies of multiple candidate genes for Parkinson's disease using single nucleotide polymorphisms. Ann Neurol, 2002. 51(1): p. 133-6.
88. Leroy, E., et al., The ubiquitin pathway in Parkinson's disease. Nature, 1998. 395(6701): p. 451-2.
89. Zhou, Y., et al., Analysis of alpha-synuclein-associated proteins by quantitative proteomics. J Biol Chem, 2004. 279(37): p. 39155-64.
90. Zhang, M., et al., Control of BACE1 degradation and APP processing by ubiquitin carboxyl-terminal hydrolase L1. J Neurochem, 2012. 120(6): p. 1129-38.
91. Guglielmotto, M., et al., Abeta1-42-mediated down-regulation of Uch-L1 is dependent on NF-kappaB activation and impaired BACE1 lysosomal degradation. Aging Cell, 2012. 11(5): p. 834-44.
92. Liu, Y., et al., The UCH-L1 gene encodes two opposing enzymatic activities that affect alpha-synuclein degradation and Parkinson's disease susceptibility. Cell, 2002. 111(2): p. 209-18.
93. Sun, S., et al., Lack of association between UCHL1 S18Y gene polymorphism and Parkinson's disease in the Asian population: a meta-analysis. Neurol Sci, 2014. 35(12): p. 1867-76.
94. Osaka, H., et al., Ubiquitin carboxy-terminal hydrolase L1 binds to and stabilizes monoubiquitin in neuron. Hum Mol Genet, 2003. 12(16): p. 1945-58.
95. Gong, B., et al., Ubiquitin hydrolase Uch-L1 rescues beta-amyloid-induced decreases in synaptic function and contextual memory. Cell, 2006. 126(4): p. 775-88.
96. Henley, D., et al., Preliminary Results of a Trial of Atabecestat in Preclinical Alzheimer's Disease. N Engl J Med, 2019. 380(15): p. 1483-1485.
97. Das, C., et al., Structural basis for conformational plasticity of the Parkinson's disease-associated ubiquitin hydrolase UCH-L1. Proc Natl Acad Sci U S A, 2006. 103(12): p. 4675-80.
98. Choi, J., et al., Oxidative modifications and down-regulation of ubiquitin carboxyl-terminal hydrolase L1 associated with idiopathic Parkinson's and Alzheimer's diseases. J Biol Chem, 2004. 279(13): p. 13256-64.
99. Rydning, S.L., et al., Novel UCHL1 mutations reveal new insights into ubiquitin processing. Hum Mol Genet, 2017. 26(6): p. 1031-1040.
100. Mitsui, T., et al., Identification of a novel chemical potentiator and inhibitors of UCH-L1 by in silico drug screening. Neurochem Int, 2010. 56(5): p. 679-86.
101. Boudreaux, D.A., et al., Ubiquitin vinyl methyl ester binding orients the misaligned active site of the ubiquitin hydrolase UCHL1 into productive conformation. Proc Natl Acad Sci U S A, 2010. 107(20): p. 9117-22.
102. Davies, C.W., et al., The co-crystal structure of ubiquitin carboxy-terminal hydrolase L1 (UCHL1) with a tripeptide fluoromethyl ketone (Z-VAE(OMe)-FMK). Bioorg Med Chem Lett, 2012. 22(12): p. 3900-4.